Depo-Provera Lawsuit 2026: Daubert Hearing and Settlement Update

My name is Mason Arnao, and my background in data systems, technology infrastructure, and digital advocacy has given me a deep understanding of how the Depo-Provera lawsuit 2026 affects real people navigating complex legal and medical systems. As publisher of TortAdvisor.com and President of Waypoint Software, I’ve spent over 20 years building systems that connect people with critical information. In this guide, I’ll break down everything you need to know to understand your rights and take action.

The Depo-Provera lawsuit 2026 has reached a critical inflection point. As of September 1, 2026, 6,403 actions were pending in MDL 3140 in the Northern District of Florida, and a settlement announced on June 15, 2026 covers a majority of the claims. The court set its hearing on the Daubert (Rule 702) challenges to expert testimony for September 18, 2026; those rulings apply to the cases that do not settle. Women who were diagnosed with meningioma brain tumors after receiving Depo-Provera (medroxyprogesterone acetate) injections are asserting that Pfizer and its subsidiary Pharmacia failed to adequately warn them of this devastating risk — despite decades of scientific evidence linking synthetic progestins to meningioma growth. If you or a loved one received Depo-Provera injections and later developed a meningioma, you may be entitled to significant financial compensation. This guide covers the latest 2026 developments, who qualifies, and how to protect your legal rights before the statute of limitations expires.

SourceJPML MDL report1 Sep 2026N.D. Fla. CMO 1227 Jul 2026

Depo-Provera Lawsuit 2026: Latest Daubert Hearing Updates

The Depo-Provera lawsuit 2026 is entering one of its most consequential phases. In MDL 3140, presiding Judge M. Casey Rodgers set the hearing on the parties’ Daubert (Rule 702) motions — the gatekeeping procedure by which federal courts determine whether expert scientific testimony meets the standards necessary to go before a jury — for September 18, 2026. Because of the June 2026 settlement, the rulings will not affect plaintiffs who are eligible for the settlement and choose to participate; they will apply to cases that are ineligible or opt out.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. MDL 3140

The scientific basis for the Depo-Provera meningioma link has grown substantially over the past several years. A 2024 national case-control study published in The BMJ found that prolonged use (one year or more) of injectable medroxyprogesterone acetate — the active ingredient in Depo-Provera — was associated with an increased risk of intracranial meningioma. The study compared 18,061 women in France who had surgery for intracranial meningioma with 90,305 matched controls. According to research published on the National Institutes of Health, meningiomas are the most common type of primary brain tumor, and hormonal factors — particularly progestin exposure — are increasingly recognized as significant risk factors.

SourceBMJ 2024;384:e07807827 Mar 2024

Pfizer’s defense strategy has centered on challenging the strength of the epidemiological evidence, arguing that the BMJ study and others relied upon by plaintiffs contain methodological flaws. Defense attorneys have sought to exclude multiple plaintiff experts on grounds that their causation opinions do not satisfy the Daubert standard of reliability. Plaintiffs’ attorneys counter that decades of peer-reviewed research — including studies from the FDA and academic medical centers — establish a biologically plausible and statistically significant link that well exceeds Daubert requirements.

The June 2026 settlement changed the trial calendar. With the announcement on June 15, the court vacated the scheduling order for the Pilot (bellwether) cases — because those plaintiffs are eligible to participate in the settlement — and cancelled the December 2026 trial in the first Pilot case, Toney v. Pfizer. The defendants then selected three cases to substitute as new Pilot cases, which the court approved on July 27, 2026. For cases that do not settle, the Rule 702 rulings will decide which expert opinions a jury can hear.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 1026 Jan 2026

The parties’ general causation summary judgment and related Rule 702 motions were fully briefed as of June 5, 2026. On June 15, 2026, the court continued the hearing from June 24–25 to July 27, 2026, and it later set the hearing for September 18, 2026. No ruling had been posted on the court’s MDL page as of September 24, 2026.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. PTO 30A15 Jun 2026N.D. Fla. MDL 3140

Meanwhile, cases have continued to accumulate: the Judicial Panel on Multidistrict Litigation counted 6,403 actions pending in MDL 3140 on September 1, 2026. The settlement’s terms are confidential, and no per-case amounts have been disclosed.

SourceJPML MDL report1 Sep 2026N.D. Fla. CMO 1227 Jul 2026

What Is a Meningioma and How Does Depo-Provera Cause It?

To understand the Depo-Provera lawsuit, it is essential to understand the injury at its center: meningioma. A meningioma is a tumor that arises from the meninges — the three layers of protective membranes that surround the brain and spinal cord. While most meningiomas are benign (non-cancerous), they are far from harmless. As these tumors grow, they press against the brain and other vital structures, causing symptoms that can be debilitating and life-altering.

Common meningioma symptoms include severe and persistent headaches, vision problems (blurring, double vision, or loss of peripheral vision), hearing loss or ringing in the ears, memory problems and cognitive impairment, weakness or numbness in the arms or legs, seizures, and in some cases, personality changes and depression. Many patients require brain surgery — a craniotomy — to remove the tumor, followed by radiation therapy to prevent recurrence. Recovery can take months to years, and some patients experience permanent neurological deficits.

The mechanism linking Depo-Provera to meningioma growth is increasingly well understood. Meningiomas express progesterone receptors, meaning they are hormonally sensitive tumors. Depo-Provera’s active ingredient, medroxyprogesterone acetate (MPA), is a synthetic progestin that binds to these receptors and can stimulate tumor growth. The longer a woman uses Depo-Provera, and the higher the cumulative dose, the greater the potential for meningioma development or accelerated growth.

Research published in peer-reviewed journals has consistently found elevated meningioma risk in women who use high-dose progestins. The 2024 BMJ study was particularly significant because it examined injectable medroxyprogesterone acetate — the drug in Depo-Provera — and found the excess risk was linked to prolonged use of one year or more. Critics of Pfizer argue that the company knew or should have known about this risk for decades and failed to include adequate warnings in Depo-Provera’s prescribing information.

SourceBMJ 2024;384:e07807827 Mar 2024

Since December 2025, the U.S. prescribing information for Depo-Provera CI has carried a meningioma warning (section 5.4): it states that cases of meningioma have been reported after repeated administration of medroxyprogesterone acetate, primarily with long-term use, and tells prescribers to discontinue the drug if a meningioma is diagnosed. Plaintiffs argue that Pfizer should have updated its label earlier, as the scientific evidence accumulated. You can review the FDA’s Depo-Provera safety communications for more background on the regulatory history of this drug.

SourceDepo-Provera CI labelRev. 12/2025

For women diagnosed with meningioma after using Depo-Provera, the emotional and financial toll is enormous. Many describe undergoing terrifying brain surgeries without knowing that the contraceptive they trusted for years may have been the cause. The Depo-Provera lawsuit represents an opportunity for these women to hold Pfizer accountable and receive the compensation they deserve for their pain, medical expenses, lost wages, and diminished quality of life.

Who Qualifies for the Depo-Provera Lawsuit?

If you received Depo-Provera (medroxyprogesterone acetate) injections and later developed a meningioma, you may be eligible to join the Depo-Provera lawsuit 2026. Eligibility criteria are based on the nature of your Depo-Provera use and your diagnosis. Below is the general qualification checklist that attorneys use when evaluating cases:

• You received Depo-Provera injections — typically administered every three months (the standard 150mg/mL dosing schedule)
• Duration of use was significant — most cases involve use of one year or more, with stronger cases involving three or more years of use
• You were diagnosed with a meningioma — confirmed by MRI, CT scan, biopsy, or surgical pathology report
• Your meningioma diagnosis came after Depo-Provera use — or the tumor was found to have grown or progressed during your use of the drug
• Your meningioma required medical treatment — including watchful waiting with documented symptoms, surgery, radiation therapy (stereotactic radiosurgery or external beam), or a combination
• You are within the statute of limitations — deadlines vary by state, but most give victims 2-3 years from the date they discovered or should have discovered the connection between Depo-Provera and their meningioma
• You are a U.S. resident — MDL 3140 covers claims filed in U.S. federal courts

Cases involving more severe meningiomas — those that required surgery, caused permanent neurological damage, or significantly impacted quality of life — are generally assigned higher settlement values. If you are uncertain whether you qualify, the best step is to call 855-664-8713 for a free, confidential case evaluation. Our team can review your Depo-Provera usage history and medical records to determine whether you have a viable claim.

It is also worth noting that family members of deceased victims may be able to file wrongful death claims in certain circumstances. If your loved one passed away from complications related to a meningioma that developed after Depo-Provera use, you may still be able to pursue compensation on their behalf. An attorney can advise you on the specific laws in your state.

Depo-Provera Settlement Amounts: What You Can Recover

A settlement was announced on June 15, 2026, and the parties signed a confidential Master Settlement Agreement on July 21, 2026. No aggregate, per-plaintiff or per-tier amounts have been published, so any dollar figure you see for this settlement is an estimate, not a disclosed number.

SourceN.D. Fla. CMO 1227 Jul 2026

What an individual claim receives will depend on the settlement’s confidential terms and the facts of your case. To discuss your specific case, contact our team at 855-664-8713.

Recoverable damages in Depo-Provera claims typically include past and future medical expenses (surgery, radiation, follow-up care, medication), lost wages and diminished earning capacity, pain and suffering, emotional distress, loss of enjoyment of life, and in some cases, punitive damages if Pfizer’s conduct is found to have been especially egregious. You can also review our general settlement calculator for broader context on how mass tort settlements are calculated.

How to File a Depo-Provera Lawsuit in 2026

Filing a Depo-Provera claim in 2026 is a straightforward process when you work with an experienced mass tort attorney. Here is a step-by-step overview of what to expect:

1. Free Case Evaluation (Day 1): Call 855-664-8713 or complete an online intake form. A case specialist will review your Depo-Provera usage history and your meningioma diagnosis to determine whether you likely qualify for the litigation.
2. Attorney Matching (Days 1–3): If your case appears viable, you will be connected with a mass tort attorney who handles Depo-Provera cases. These attorneys work on a contingency fee basis — meaning you pay nothing unless and until you receive compensation.
3. Medical Records Collection (Weeks 1–4): Your attorney will gather your Depo-Provera prescription and administration records, imaging studies (MRI/CT scans), surgical and pathology reports, and any other medical documentation relevant to your diagnosis and treatment.
4. Complaint Filed (Weeks 4–8): Your attorney will prepare and file a formal complaint in federal court. Federal Depo-Provera cases are consolidated in MDL 3140 in the Northern District of Florida, alongside thousands of similar claims.
5. Discovery Phase (Months 2–18+): Both sides exchange documents and conduct depositions. In an MDL, much of this discovery is done at the consolidated level, so individual plaintiffs typically do not need to be deposed.
6. Settlement or Continued Litigation: A settlement covering a majority of MDL claims was announced on June 15, 2026, and the deadline for claimants to register for the Settlement Program is November 30, 2026. Plaintiffs who do not participate must meet case-specific discovery deadlines under Case Management Order No. 14. Your attorney will explain the terms and whether your case qualifies.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 1410 Aug 2026

Use Our Free Depo-Provera Settlement Calculator

To get an estimate of what your claim may be worth, visit the Depo-Provera settlement calculator. Simply enter information about your treatment history, duration of Depo-Provera use, and injury severity to receive a personalized estimate based on comparable mass tort settlements.

MDL 3140 Case Status and Timeline

MDL 3140 — In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation — is pending before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida, where the Judicial Panel on Multidistrict Litigation centralized it on February 7, 2025. Here is the current status as of September 24, 2026:

SourceN.D. Fla. MDL 3140

Total Cases Pending: 6,403 actions were pending in MDL 3140 as of September 1, 2026, according to the Judicial Panel on Multidistrict Litigation.

SourceJPML MDL report1 Sep 2026

Daubert (Rule 702) Motions: Fully briefed as of June 5, 2026. The hearing moved from June 24–25 to July 27, then to September 18, 2026; no ruling had been posted on the court’s MDL page as of September 24, 2026. The rulings will determine which expert witnesses can testify in cases that do not settle.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. PTO 30A15 Jun 2026

Pilot (Bellwether) Trials: With the settlement announcement, the court cancelled the December 2026 trial in the first Pilot case (Toney v. Pfizer), because the original Pilot plaintiffs are eligible to participate in the settlement. Three substitute Pilot cases were approved on July 27, 2026.

SourceN.D. Fla. CMO 1026 Jan 2026N.D. Fla. CMO 1227 Jul 2026

Settlement: Announced June 15, 2026; the confidential Master Settlement Agreement was signed July 21, 2026. The parties estimate roughly 80% of MDL plaintiffs are eligible. The registration deadline is November 30, 2026, and the court’s order anticipates payments beginning to roll out by the first quarter of 2027. No amounts have been made public.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 1410 Aug 2026

If you used Depo-Provera and developed a meningioma, it is critical that you file your claim as soon as possible. Statutes of limitations in most states run 2–3 years from the date you discovered (or should have discovered) the connection between your drug use and your injury. The clock is ticking. Contact us at 855-664-8713 to get started today.

Frequently Asked Questions: Depo-Provera Lawsuit 2026

About the Author

Mason Arnao is the President and Managing Partner of Waypoint Software, LLC — a leading U.S. software development and digital advocacy firm based in South Florida. With over 20 years of experience in data systems, technology infrastructure, and digital research, Mason has developed deep expertise in how pharmaceutical failures like the Depo-Provera meningioma litigation affect everyday people navigating complex legal systems. As publisher of TortAdvisor.com, Mason is committed to connecting injured victims with the information and legal resources they need to take action.

SourceN.D. Fla. CMO 1227 Jul 2026JPML MDL report1 Sep 2026

Last Updated: September 24, 2026 | Published by: Mason Arnao | Primary Sources: JPML MDL docket records, court filings.